Boosters and new versions of vaccines that target the Covid variants are already being explored by both Pfizer and Moderna.
May 24, 2021
The medicines will be made available immediately and we will ensure that they reach where they are needed the most, Pfizer CEO Albert Bourla said
May 3, 2021
Meanwhile, Pfizer has issued a statement, saying that it has withdrawn its application for now and would re-apply with the additional data in hand sought by the SEC.
February 6, 2021
They also outlined steps on safely receiving the second dose in individuals who develop a reaction to their first dose of Covid-19 vaccine.
January 1, 2021
Bourla made the comment when asked, "Are you working on versions of your vaccine that can be stored in less extreme temperature in countries like India?"
December 9, 2020
The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.
September 13, 2020
The trial's primary endpoints will be the prevention of Covid-19 in those who have not been infected by SARS-CoV-2 prior to immunization, and prevention of Covid-19 regardless of whether participants have previously been infected by SARS-CoV-2.
August 26, 2020
The trial showed that volunteers given two doses of the vaccine produced virus-neutralizing antibodies, similar to the U.S. trial.
July 21, 2020